Skip to content

D&A at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.28M+30.8%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$4.11M-10.7%
HRO
HarrowHROW
$455K-2.2%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$381K-7.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$8M-11.1%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's D&A?
EyePoint, Inc. (EYPT) reported D&A of $636K in Q1 2026.
How has EyePoint, Inc. 's D&A changed year-over-year?
EyePoint, Inc. 's D&A increased by 28.0% year-over-year, from $497K to $636K.
What is the long-term trend for EyePoint, Inc. 's D&A?
Over 4 years (2021 to 2025), EyePoint, Inc. 's D&A has grown at a 65.1% compound annual growth rate (CAGR), from $311K to $2.31M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.